The story of Sildenafil presents a nuanced case for stakeholders in the pharmaceutical sector. While initially a tremendous success, generating vast sums, the exclusivity expiration and the subsequent flood of cheaper competitors have significantly impacted revenue. This raises questions about the ongoing sustainability of similar drug innovations